Comparing Cerus (CERS) & Motus GI (MOTS)
Cerus (NASDAQ: MOTS) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.
Insider and Institutional Ownership
59.8% of Cerus shares are owned by institutional investors. Comparatively, 21.6% of Motus GI shares are owned by institutional investors. 6.8% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Cerus and Motus GI’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and recommmendations for Cerus and Motus GI, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cerus presently has a consensus price target of $8.00, suggesting a potential upside of 6.52%. Motus GI has a consensus price target of $9.50, suggesting a potential upside of 90.00%. Given Motus GI’s stronger consensus rating and higher possible upside, analysts plainly believe Motus GI is more favorable than Cerus.
Earnings and Valuation
This table compares Cerus and Motus GI’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cerus||$51.33 million||19.58||-$60.58 million||($0.56)||-13.41|
|Motus GI||$10,000.00||7,840.00||-$13.20 million||($1.28)||-3.91|
Motus GI has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.
Motus GI beats Cerus on 7 of the 13 factors compared between the two stocks.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
About Motus GI
Motus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company is based in Fort Lauderdale, Florida.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.